Biliary Atresia in 2021: Epidemiology, Screening and Public Policy

Area of Science:

• Pediatric Hepatology
• Public Health
• Neonatal Diseases

Background:

• Biliary atresia (BA) is a rare but serious liver disease in newborns.
• It is a leading cause of pediatric liver failure and the primary reason for liver transplants in children.
• Early diagnosis and treatment, such as Kasai portoenterostomy (KPE), are crucial for improving patient prognosis.

Purpose of the Study:

• To examine biliary atresia from a global public health perspective.
• To review current national screening programs for BA and their effectiveness.
• To discuss novel screening initiatives and policy challenges for BA detection worldwide.

Main Methods:

• Literature review of global public health data on biliary atresia.
• Analysis of existing national screening programs for BA.
• Examination of policy challenges and case studies from North America, Europe, and Asia.

Main Results:

• Delayed diagnosis and treatment of BA remain a significant global issue.
• Current screening programs show variable impact on patient outcomes.
• Novel screening initiatives are emerging, but implementation faces policy hurdles.

Conclusions:

• Effective global public health strategies and improved screening are essential to reduce morbidity and mortality from biliary atresia.
• Addressing policy challenges is key to implementing successful BA screening programs worldwide.
• Early detection through enhanced screening can improve outcomes for children with BA, potentially reducing the need for liver transplantation.